Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Results Among patients without HIV/AIDS–related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In this video, Graff provides an overview of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), noting that they are forms of non-Hodgkin lymphoma despite the term ...

Rash isn’t the most common symptom of Hodgkin lymphoma, but oncologists say it can happen. “This is often a rash that will ...

This includes Hodgkin’s lymphoma, non-Hodgkin lymphoma, and CLL. Aiming to improve your general health can give you the best chance of lowering your cancer risk overall.

CLL-314 trial compared the efficacy and safety of pirtobrutinib with ibrutinib in adults with CLL/SLL who were treatment-naïve or who were previously treated and were BTK inhibitor-naïve.

Specifically, patients with CLL had a 92% decreased chance of severe infection, while those with non-Hodgkin lymphoma had an 86% decreased chance. According to the release, clinical guidelines vary on ...